Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.

K NugentS MukherjeeS TeohB GeorgeA MartinA GayaL Aznar-GarciaK ChuM RobinsonT MaughanJ Good

Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) (2024)

This is the first UK-reported experience of MR-guided daily adaptive pancreatic SABR. SMART shows promise in delivering ablative doses with acceptable toxicity rates and good clinical outcomes.

Keyphrases

magnetic resonance
contrast enhanced
physical activity
small cell lung cancer
cross sectional
squamous cell carcinoma
oxidative stress
big data
magnetic resonance imaging
brain metastases
machine learning